Literature DB >> 71400

Polymorphic hydroxylation of Debrisoquine in man.

A Mahgoub, J R Idle, L G Dring, R Lancaster, R L Smith.   

Abstract

Debrisoquine and its primary metabolite, 4-hydroxydebrisoquine, were measured in the urine of 94 volunteers after a single oral dose of 10 mg debrisoquine. The ratio between excreted debrisoquine and its metabolite was bimorphically distributed in the study population. Family studies supported the view that alicyclic 4-hydroxylation of debrisoquine is controlled by a single autosomal gene and that a defect in this metabolic step is caused by a recessive allele.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 71400     DOI: 10.1016/s0140-6736(77)91430-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  263 in total

1.  Pharmacogenetics and pharmacogenomics.

Authors:  M Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

Review 2.  Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

Authors:  Leif Bertilsson; Marja-Liisa Dahl; Per Dalén; Ayman Al-Shurbaji
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

Review 3.  Development of analytical technology in pharmacogenetic research.

Authors:  Ann K Daly
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-09-25       Impact factor: 3.000

4.  Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects.

Authors:  Myo-Kyoung Kim; Joo-Youn Cho; Hyeong-Seok Lim; Kyoung-Seop Hong; Jae-Yong Chung; Kyun-Seop Bae; Dal-Seok Oh; Sang-Goo Shin; Sang-Hun Lee; Dong-Ho Lee; Bumchan Min; In-Jin Jang
Journal:  Eur J Clin Pharmacol       Date:  2003-05-01       Impact factor: 2.953

5.  Inhibitors of imipramine metabolism by human liver microsomes.

Authors:  E Skjelbo; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

6.  Perturbation of paracetamol urinary metabolic ratios by urine flow rate.

Authors:  J O Miners; N J Osborne; A L Tonkin; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

7.  Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers.

Authors:  T Graf; F Broly; F Hoffmann; M Probst; U A Meyer; H Howald
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

8.  Polymorphic metabolism of metoprolol: clinical studies.

Authors:  J H Silas; J C McGourty; M S Lennard; G T Tucker; H F Woods
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.

Authors:  J C McGourty; J H Silas; M S Lennard; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

Review 10.  Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.

Authors:  Katarzyna Drozda; Daniel J Müller; Jeffrey R Bishop
Journal:  Pharmacotherapy       Date:  2014-02       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.